Ranking by Regions
United States
Canada
Mexico
Brazil
Chile
Germany
United Kingdom
France
Spain
Netherlands
Sweden
Italy
Switzerland
Poland
Finland
China
Japan
South Korea
Hong Kong
Singapore
Indonesia
India
Malaysia
Taiwan
Thailand
Australia
New Zealand
Israel
Saudi Arabia
Turkey
Russia
South AfricaRanking by categories
As of April 15, 2025, Genmab (GMAB) has a market cap of $11.92 billion USD. According to our data, Genmab is ranked No.1396 in global market value.
| Year | Market Cap | %Change |
|---|---|---|
| Apr 15, 2025 | $11.92 B |
-10.15%
|
| Dec 31, 2024 | $13.26 B |
-34.45%
|
| Dec 29, 2023 | $20.23 B |
-24.87%
|
| Dec 30, 2022 | $26.93 B |
7.13%
|
| Dec 31, 2021 | $25.14 B |
-2.71%
|
| Dec 31, 2020 | $25.84 B |
82.09%
|
| Dec 31, 2019 | $14.19 B |
35.54%
|
| Dec 31, 2018 | $10.47 B |
-0.61%
|
| Dec 29, 2017 | $10.53 B |
-0.04%
|
| Dec 30, 2016 | $10.54 B |
23.73%
|
| Dec 31, 2015 | $8.52 B |
128.70%
|
| Dec 31, 2014 | $3.72 B |
49.72%
|
| Dec 31, 2013 | $2.49 B |
179.57%
|
| Dec 31, 2012 | $0.89 B |
114.07%
|
| Dec 30, 2011 | $0.42 B |
-51.56%
|
| Dec 31, 2010 | $0.86 B |
-10.60%
|
| Dec 31, 2009 | $0.96 B |
100%
|
| Name | Market Cap | Market cap difference | Regions |
|---|---|---|---|
 Novartis
NVS
|
$217.12 B |
0.003 M
|
Switzerland
|
 Amgen
AMGN
|
$158.77 B |
0.132 B
|
USA
|
 Bristol-Myers Squibb
BMY
|
$101.74 B |
-0.001 M
|
USA
|
 Merck
MRK
|
$197.26 B |
0.003 M
|
USA
|
 Pfizer
PFE
|
$127.27 B |
-0.003 M
|
USA
|
 Johnson & Johnson
JNJ
|
$370.20 B |
0.003 M
|
USA
|
 Gilead Sciences
GILD
|
$131.74 B |
-0.002 M
|
USA
|
 Regeneron Pharmaceuticals
REGN
|
$60.99 B |
1.014 B
|
USA
|
 AbbVie
ABBV
|
$312.76 B |
-0.013 M
|
USA
|
 Sanofi
SNY
|
$123.58 B |
-0.002 M
|
France
|
 AstraZeneca
AZN
|
$210.42 B |
-0.005 M
|
UK
|
 Biogen
BIIB
|
$17.12 B |
0.000 M
|
USA
|
 Eli Lilly
LLY
|
$679.94 B |
-0.022 M
|
USA
|
 GlaxoSmithKline
GSK
|
$72.33 B |
-0.002 M
|
UK
|
| Market Cap | = | GMAB Stock Price | * | GMAB Shares Outstanding |
| = | $19.51 | * | 0.61 B | |
| = | $11.92 B |